Physicochemical Properties
| Molecular Formula | C24H20CLNO2 |
| Molecular Weight | 389.87 |
| CAS # | 2758520-84-0 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Compound 11 (antitumor agent-80) (5 μM, 48 h) causes tumor cells to undergo apoptosis and exhibit increased PARP cleavage[1]. In vitro, antitumor agent-80 (0–10 μM, 96 h) inhibits the development of breast and hepatocellular cancer cell lines[1]. Antitumor agent-80's growth-inhibitory activity against a panel of breast cancer cells and hepatocellular carcinoma[1]. Huh7 1.3 MCF7 3.8 HepG2 2.1 MDA-MB231 2.0 SNU475 1.7 MDA-MB468 2.8 Hep3B 3.0 SKBR3 3.5 FOCUS 2.1 ZR75 7.6 Hep40 8.6 MCF10A 12.1 PLC-PRF-5 9.5 Mahlavu 3.2 Hepatocellular carcinoma IC50 (μM) breast |
| ln Vivo | Antitumor agent-80 (compound 11) has antitumor activity in vivo in the Mahlavu hepatocellular carcinoma and MDA-MB-231 breast cancer xenograft models at a dose of 40 mg/kg orally twice a week for a duration of 4 weeks[1]. |
| Cell Assay |
Western Blot Analysis[1] Cell Types: Huh7, Mahlavu, MDA-MB-231, and MCF-7 cells Tested Concentrations: 5 μM Incubation Duration: 48 h Experimental Results: Caused the increase in PARP cleavage in both breast cancer cells (MCF7 and MDA -MB-231) and hepatocellular carcinoma cells (Mahlavu). Cell Proliferation Assay[1] Cell Types: Huh7, Mahlavu, MDA-MB-231, and MCF-7 cells Tested Concentrations: 10 μM, 5 μM, 2.5 μM Incubation Duration: 96 h Experimental Results: Caused inhibition in the growth of both breast and hepatocellular carcinoma cell lines. |
| Animal Protocol |
Animal/Disease Models: Athymic nude mice (6-8 weeks old, with Mahlavu cells or MDA-MB-231 cells)[1] Doses: 40 mg/kg Route of Administration: Orally, twice a week, for 4 weeks Experimental Results: In the Mahlavu xenografts, had a significant reduction (85%) in tumor volume. For MDA-MB-231 xenografts, resulted in about a 50% decrease in tumor volumes as compared to the control group. |
| References | [1]. Turanlı S, et al. Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with In Vitro Growth Inhibitory and In Vivo Antitumor Activity. ACS Omega. 2022 Oct 3;7(41):36206-36226. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5650 mL | 12.8248 mL | 25.6496 mL | |
| 5 mM | 0.5130 mL | 2.5650 mL | 5.1299 mL | |
| 10 mM | 0.2565 mL | 1.2825 mL | 2.5650 mL |